Abstract
The proportion of trough plasma concentration of dolutegravir (DTG) above protein adjusted 90% inhibition concentration (IC90) (0.064mg/L) was 98.1% across all visits during the twelve doses of once-weekly rifapentine and isoniazid (3HP) in people with HIV (PWH). Furthermore, the participants maintained a high rate of HIV viral suppression (98%) within 6 months after completing 3HP.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call